FENNEC PHARMACEUTICALS
Fennec Pharmaceuticals Inc. (TSX: FRX, OTC: Interim ADHXD, Final FENCF (October 2, 2014), is a clinical-stage biotechnology company developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. STS is being investigated in two pediatric Phase III studies to evaluate the reduction of ototoxicity and impact on survival. Originating in Saharan North Africa, the fennec fox is the smallest of the foxes and uniquely adapted to high temperat... ures and low water environments. It has distinctively large ears which dissipate heat and provide a very sensitive hearing. These qualities of adaptability and resourcefulness led us to adopt the fox with the big ears as our new name and logo. Children undergoing chemotherapy are going through an extraordinarily challenging time and the loss of hearing only compounds the difficulty. Fennec Pharma, named after that resourceful and determined fennec fox hopes that STS will allow these children to keep their hearing and prevent permanent disability. As the company refocuses on this mission, it seemed appropriate to adopt the fox with the big ears as our new name and logo.
FENNEC PHARMACEUTICALS
Industry:
Biopharma Biotechnology Health Care Pharmaceutical
Founded:
1996-01-01
Address:
Durham, North Carolina, United States
Country:
United States
Website Url:
http://www.fennecpharma.com
Total Employee:
1+
Status:
Active
Contact:
(919) 636-4530
Email Addresses:
[email protected]
Total Funding:
58.3 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network
Similar Organizations
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Entos Pharmaceuticals
Entos Pharmaceuticals is a healthcare biotechnology company that develops nucleic acid therapies.
X4 Pharmaceuticals
X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment.
Current Advisors List
Current Employees Featured
Stock Details
Investors List
Petrichor Healthcare Capital Management
Petrichor Healthcare Capital Management investment in Post-IPO Equity - Fennec Pharmaceuticals
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Convertible Note - Fennec Pharmaceuticals
Official Site Inspections
http://www.fennecpharma.com
- Host name: cloudproxy10107.sucuri.net
- IP address: 192.124.249.107
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Fennec Pharmaceuticals"
Fennec Pharmaceuticals - Crunchbase Company Profile …
Contact Email [email protected] Phone Number (919) 636-4530 Fennec Pharmaceuticals Inc. (TSX: FRX, OTC: Interim ADHXD, Final FENCF (October 2, 2014), is a clinical-stage biotechnology company developing Sodium …See details»
Fennec Pharmaceuticals Inc. (FENC) - Yahoo Finance
See the company profile for Fennec Pharmaceuticals Inc. (FENC) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Overview, News & Similar companies - ZoomInfo.com
May 16, 2024 View Fennec Pharmaceuticals (www.fennecpharma.com) location in North Carolina, United States , revenue, industry and description. Find related and similar …See details»
FENC - Fennec Pharmaceuticals, Inc. | Company Profile | OTC …
Dec 31, 2024 www.fennecpharma.com (919) 636-4530. [email protected]. Business Description. ... He also served as the Managing Director at Accelera S.r.l., an independent …See details»
Fennec Pharmaceuticals Inc. (FENC) Company Profile & Overview
Jun 5, 2001 Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium …See details»
Fennec Pharmaceuticals Inc | LinkedIn
Fennec Pharmaceuticals Inc | 3,400 followers on LinkedIn. Fiercely devoted to the fight against ototoxicity in pediatric cancer patients who receive cisplatin-based chemotherapy. | Fiercely ...See details»
Fennec Pharmaceuticals Company Description - Stock Analysis
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the …See details»
Fennec Pharmaceuticals Inc. (FENC) - Yahoo Finance Canada
See the company profile for Fennec Pharmaceuticals Inc. (FENC) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Fennec Pharma - Craft
Jul 10, 2024 Fennec Pharma has 5 employees at their 1 location and $21.25 m in annual revenue in FY 2023. See insights on Fennec Pharma including office locations, competitors, …See details»
Fennec Pharmaceuticals Inc. (FENC) - Stock Analysis
3 days ago Website https://www.fennecpharma.com. Full Company Profile. Financial Performance. In 2023, Fennec Pharmaceuticals's revenue was $21.25 million, an increase of …See details»
Fennec Pharmaceuticals Strengthens Executive Leadership Team …
Oct 28, 2024 “Building an experienced, multi-talented executive leadership team is a critical step for Fennec as we embark on a new chapter in the organization’s evolution, and I am delighted …See details»
FENNEC PHARMACEUTICALS ANNOUNCES SECOND QUARTER …
Aug 12, 2022 As previously disclosed on August 1, 2022, Fennec announced up to a $45 million investment from Petrichor Healthcare Capital Management (“Petrichor”). Additional details …See details»
Fennec Pharmaceuticals Strengthens Executive Leadership Team …
Oct 28, 2024 For more information, please visit www.fennecpharma.com. Forward Looking Statements Except for historical information described in this press release, all other …See details»
Fennec Pharmaceuticals Strengthens Executive Leadership
Oct 28, 2024 “Building an experienced, multi-talented executive leadership team is a critical step for Fennec as we embark on a new chapter in the organization’s evolution, and I am delighted …See details»
Fennec Pharmaceuticals Reports Second Quarter 2024 Financial …
Aug 13, 2024 Fennec Pharmaceuticals Inc. ~ Achieved Second Quarter 2024 Total Net Revenues of $7.3 Million ~ ~ Appointed Jeffrey S. Hackman as Chief Executive Officer (CEO) …See details»
Fennec Pharmaceuticals Reports Preliminary Unaudited Net …
Feb 29, 2024 ~ Fourth Quarter 2023 Net Revenues of Approximately $9.2 to $9.7 Million ~ ~ Company Expects to Report 2023 Fourth Quarter and Audited Full-Year Results on or about …See details»
Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 ...
Mar 21, 2024 ~ Achieved PEDMARK ® Full-Year 2023 Net Product Sales of $21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023 ~ ~ Entered Into …See details»
Fennec Pharmaceuticals Reports First Quarter 2024 Financial …
May 14, 2024 Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.fennecpharma.com and proceed to the News & …See details»
Fennec Pharmaceuticals Announces Second Quarter 2022 …
Aug 12, 2022 We are focused on ensuring readiness for our PDUFA target action date of September 23, 2022, and have built out our commercial organization with key hires, including …See details»
Fennec Pharmaceuticals Announces Up to $45 Million Investment …
Aug 1, 2022 Fennec has a license agreement with Oregon Health and Science University (OHSU) for exclusive worldwide license rights to intellectual property directed to sodium …See details»